Tag: ACHN

Blue Horseshoe Stocks: RAD, ACHN Recaps & More

Achillon Pharmaceuticals, Inc. ACHN

ACHN stood out amongst the stocks we discussed in yesterday’s morning report. The move came in conjunction with the announcement that the company’s Hep C treatment currently in trials had successfully cured all of the patients in the latest clinical test.

As a result ACHN ran from a morning low of 14.56 on up to 16.87 for a solid 16% intraday move, on its highest volume traded since June.

We’ve been tracking ACHN for over a month now, and in that time have observed a low of 12.00 (Nov. 12th). As of yesterday’s high, that represents an overall increase of 40% in a relatively short amount of time.

Rite-Aid Corp. RAD

We began paying attention to RAD on Tuesday of last week, and the stock has made some good progress since then. Yesterday was no exception, with RAD adding another 6% to the healthy upward movements we’ve already witnessed.

From the low of 5.79 we observed last Tuesday after adding it to our watchlist for the first time, to yesterday’s high of 7.19, equates to a move of 25% in a span of just five sessions. That’s more than enough to hold our attention as we head into the New Year.

It’s worth mentioning that the Cowen Group investment research arm upgraded RAD from a ‘Neutral’ to an ‘Outperform’ rating, with a price target of 8.50/share, and one of our favorite sites, BARCHART.com is currently rating RAD a 100% Short-Term ‘Buy’, with an 88% ‘Buy’ Rating overall.

Extended Watchlist:
NQ, ARIA, ALSK, CYTK, ICLD, DRYS

Blue Horseshoe Stocks: TRXC Recap & Much More

TransEnterix Inc. TRXC

TRXC stood out among the other mentions in Friday’s premarket report. Following our tag of this stock it shot quite rapidly from an early low of 2.73, and reached a subsequent high of 4.05 shortly after 11AM EST.

We want to congratulate any of our reader who were able to take advantage of that timely alert which yielded the opportunity at intraday gains of up to 48%  The healthy spike came on nearly tenfold the 3-month average trading volume.

Friday’s move came in conjunction with the announcement of successful pre-clinical trials for its SurgiBot minimally invasive surgery system. Two different doctors used TRXC’s product in actual medical procedures and subsequently offered their endorsements. It is an important step on the way to FDA application submission, which the company has stated should be on the table by mid-2015. Thus, TRXC may be one that we’ll want to have on a more long-term watch.

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of robotics and flexible instruments to improve minimally invasive surgery, today announced the successful completion of four general surgery and urology procedures using its SurgiBot system patient-side robotic surgery system. >> FULL PR

The First Marblehead Corp. FMD

We also wanted to give a quick nod to FMD for a solid performance following its inclusion in Friday morning’s watchlist. The stock found a low of 4.65 within the first several minutes of the open, and would go on to end the day with a on a high note, reaching as high as 5.35 and marking a respectable intraday move of 15%

Nuvilex, Inc. NVLX

Our first mention of NVLX dates all way back to August of 2013 when we released a special report on the company and its pancreatic cancer treatment, which at the time was in the early stages of Phase-2 trials. (Read the Special Report HERE)

A major development hit the presswires this morning regarding the FDA’s granting of ‘Orphan Drug’ status to that treatment, so we wanted to bring the stock back into the mix.

It’s coming off of a recent bottom as well, so NVLX is certainly going to be reserved a spot on our watchlist as the story continues to play out. The company has stated that Phase-3 trials should begin in 2015.

SILVER SPRING, Md., Dec. 22, 2014 (GLOBE NEWSWIRE) — Nuvilex, Inc. (NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Nuvilex orphan drug designation for its pancreatic cancer treatment. >> FULL PR

Rite-Aid Corp. RAD

We tagged RAD for tracking this past Tuesday, and the stock responded with a respectable performance on the week. An earnings beat as well as heightened guidance facilitated a healthy move from a low of 5.73 to a subsequent high of 7.05, marking a 23% intraweek spike.

Extended Watchlist:
GSS(Bottom Bouncer coming off 52-week lows), CANF, APP, TGE, ACHN

Blue Horseshoe Stocks: Happy Veteran’s Day

Achillion Pharmceuticals, Inc. ACHN

Those of you who don’t remember, we followed ACHN to enormous gains this past summer, beginning with our first mention of the stock on June 9th. After that time we actually saw this play run from a low of 3.72 to more than 13.00.

We re-tagged it in yesterday’s extended watchlist and were happy with the timing;  the stock traded in a range from 10.67 up to 12.95, a healthy 21% intraday move on more than four times the 1-month average volume.

Planar Systems, Inc. PLNR

We also wanted to do a quick update on PLNR. This stock came off of our extended watchlist on Thursday, and made a modest 15% move from 6.11-7.05, and it put up a similar performance to start the week yesterday.

We saw a move from 6.40-7.94, an intraday gain of 24%, and at the high, an overall increase of 30% from Thursday’s observed low.

Implant Sciences Corp. IMSC

We also want to keep an eye on IMSC today, as we’re seeing the stock gap up this morning on the heels of a PR that alluded to the securing of a contract with the United States Transportation Security Administration (TSA) that apparently could be worth up to $162M.

Extended Watchlist:
ZNGA, JNUG, DNDN, LITB, THLD, ARWR